{"title":"Circuit Survival in Children with Hemolytic Uremic Syndrome Requiring Continuous Renal Replacement Therapy.","authors":"Valentine Villada, Florent Girard, Elise Jeannesson, Matthieu Maria, Cyril Schweitzer, Chloé Grosyeux, Isabelle Vrillon, Arnaud Wiedemann","doi":"10.1159/000550355","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hemolytic uremic syndrome (HUS) is a significant cause of acute kidney injury (AKI) in children that is caused by Shiga toxin-producing Escherichia coli. Continuous renal replacement therapy (CRRT) is frequently used for managing AKI in critically ill pediatric patients. The filter lifespan is a crucial factor affecting its effectiveness and cost. This study aimed to investigate the impact of HUS on the lifespan of CRRT filters compared with that of other etiologies.</p><p><strong>Materials and methods: </strong>This retrospective longitudinal study was conducted in a pediatric intensive care unit in Nancy, France, from January 2013 to December 2023. The study included 54 children requiring CRRT, with 388 filters (202 in the HUS group and 186 in the other etiologies group). Data on filter lifespan and various parameters were collected and analyzed according to disease (HUS group or other etiologies) and the type of anticoagulation used.</p><p><strong>Results: </strong>The median lifespan of the filters in the HUS group was shorter than that in the other etiologies group (13.3 h vs. 17.6 h, p = 0.05). This study revealed no significant difference in filter lifespan between regional citrate anticoagulation and systemic unfractionated heparin in pediatric patients with typical HUS (p = 1.00).</p><p><strong>Conclusion: </strong>The prothrombotic nature of HUS, characterized by platelet activation, may contribute to the observed decrease in lifespan. The mechanism of coagulation activation in HUS and its interaction with hemofiltration, including the effects of platelets and blood product transfusions, remain to be explored. The lifespan of the filters is shorter in patients with HUS than in those with other etiologies, regardless of the type of anticoagulation used.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"296-309"},"PeriodicalIF":2.2000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Purification","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000550355","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Hemolytic uremic syndrome (HUS) is a significant cause of acute kidney injury (AKI) in children that is caused by Shiga toxin-producing Escherichia coli. Continuous renal replacement therapy (CRRT) is frequently used for managing AKI in critically ill pediatric patients. The filter lifespan is a crucial factor affecting its effectiveness and cost. This study aimed to investigate the impact of HUS on the lifespan of CRRT filters compared with that of other etiologies.
Materials and methods: This retrospective longitudinal study was conducted in a pediatric intensive care unit in Nancy, France, from January 2013 to December 2023. The study included 54 children requiring CRRT, with 388 filters (202 in the HUS group and 186 in the other etiologies group). Data on filter lifespan and various parameters were collected and analyzed according to disease (HUS group or other etiologies) and the type of anticoagulation used.
Results: The median lifespan of the filters in the HUS group was shorter than that in the other etiologies group (13.3 h vs. 17.6 h, p = 0.05). This study revealed no significant difference in filter lifespan between regional citrate anticoagulation and systemic unfractionated heparin in pediatric patients with typical HUS (p = 1.00).
Conclusion: The prothrombotic nature of HUS, characterized by platelet activation, may contribute to the observed decrease in lifespan. The mechanism of coagulation activation in HUS and its interaction with hemofiltration, including the effects of platelets and blood product transfusions, remain to be explored. The lifespan of the filters is shorter in patients with HUS than in those with other etiologies, regardless of the type of anticoagulation used.
期刊介绍：
Practical information on hemodialysis, hemofiltration, peritoneal dialysis and apheresis is featured in this journal. Recognizing the critical importance of equipment and procedures, particular emphasis has been placed on reports, drawn from a wide range of fields, describing technical advances and improvements in methodology. Papers reflect the search for cost-effective solutions which increase not only patient survival but also patient comfort and disease improvement through prevention or correction of undesirable effects. Advances in vascular access and blood anticoagulation, problems associated with exposure of blood to foreign surfaces and acute-care nephrology, including continuous therapies, also receive attention. Nephrologists, internists, intensivists and hospital staff involved in dialysis, apheresis and immunoadsorption for acute and chronic solid organ failure will find this journal useful and informative. ''Blood Purification'' also serves as a platform for multidisciplinary experiences involving nephrologists, cardiologists and critical care physicians in order to expand the level of interaction between different disciplines and specialities.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
